Table 2 Comparison of patient and clinical risk factors in training and validation group
Training group (n = 141) | Validation group (n = 59) | |||||
|---|---|---|---|---|---|---|
Calcified plaque group (n = 74) | Non-calcified plaque group (n = 67) | p | Calcified plaque group (n = 31) | Non-calcified plaque group (n = 28) | p | |
Age (years) | 61.95 ± 10.15 | 57.76 ± 10.04 | 0.007 | 63.58 ± 9.02 | 59.93 ± 9.92 | 0.212 |
Gender | 0.234 | 0.470 | ||||
Male | 38 (51.4%) | 46 (68.7%) | 18 (58.1%) | 14 (50.0%) | ||
Female | 36 (48.6%) | 21 (31.3%) | 13 (41.9%) | 14 (50.0%) | ||
Hypertension | 0.538 | 0.090 | ||||
Yes | 32 (43.2%) | 37 (55.2%) | 18 (58.1%) | 18 (64.3%) | ||
No | 42 (56.8%) | 30 (44.8%) | 13 (41.9%) | 10 (35.7%) | ||
Diabetes | 0.229 | 0.597 | ||||
Yes | 10 (13.5%) | 6(9.0%) | 6 (19.4%) | 5 (17.9%) | ||
No | 64 (84.5%) | 61(91.0%) | 25(80.6%) | 23 (82.1%) | ||
Hyperlipidemia | 0.248 | 0.066 | ||||
Yes | 5 (6.8%) | 6 (9.0%) | 5 (16.1%) | 2 (7.1%) | ||
No | 69 (93.2%) | 61 (91.0%) | 26 (83.9%) | 26 (92.9%) | ||
Diseased blood vessel | 0.808 | 0.226 | ||||
LM | 4 (5.4%) | 4 (6.0%) | 3 (9.7%) | 1 (3.5%) | ||
LAD | 43 (58.1%) | 40 (59.7%) | 18 (58.1%) | 16 (57.1%) | ||
D | 1 (1.4%) | 3 (4.5%) | 0 (0) | 2 (7.1%) | ||
LCx | 10 (13.5%) | 4 (6.0%) | 3 (9.7%) | 1 (3.6%) | ||
RCA | 14 (18.9%) | 15 (22.3%) | 7 (22.5%) | 8 (28.6%) | ||
PDA | 2 (2.7%) | 1 (1.5%) | 0 (0) | 0 (0) | ||